1. Place of regorafenib in treatment of patients with metastatic colorectal cancer: when are all options exhausted? Or in third line?
   A. L. Pylev et al, 2021, Medical alphabet CrossRef
2. Current concepts of anti-EGFR targeting in metastatic colorectal cancer
   Bernhard Doleschal et al, 2022, Frontiers in Oncology CrossRef
3. Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
   Chiara Cremolini et al, 2023, Frontiers in Oncology CrossRef
4. Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer
   Xiang-Bin Wan et al, 2019, World Journal of Gastroenterology CrossRef
5. Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry
   Li Chia Chong et al, 2020, Targeted Oncology CrossRef
6. Options and rationale for reinstituting anti-EGFR therapy in pretreated RAS wild-type advanced colorectal carcinomas
   Zdeněk Linke, 2023, Onkologie CrossRef
7. KRAS Gene Copy Number as a Negative Predictive Biomarker for the Treatment of Metastatic Rectal Cancer With Cetuximab: A Case Report
   Qunli Xiong et al, 2022, Frontiers in Oncology CrossRef
8. The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review
   Davide Ciardiello et al, 2024, Cancer Treatment Reviews CrossRef